STOCK TITAN

[SCHEDULE 13G/A] GLOBUS MEDICAL INC Amended Passive Investment Disclosure

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Globus Medical Inc: The Vanguard Group filed Amendment No. 13 to a Schedule 13G/A reporting 0 shares of Common Stock, representing 0% beneficial ownership as disclosed in the filing. The amendment notes an internal realignment of The Vanguard Group and separate reporting by subsidiaries January 12, 2026.

Positive

  • None.

Negative

  • None.

Insights

Vanguard reports no beneficial holding in Globus Medical following internal realignment.

The filing shows 0 shares and 0% beneficial ownership, reflecting Vanguard's disaggregated reporting after its January 12, 2026 realignment. This is a declarative ownership statement rather than a market transaction.

Future filings from the same group may show holdings by separate subsidiaries; subsequent amendments or separate Schedule 13G/A entries should be reviewed for any reappearance of positions.

Amendment cites SEC Release No. 34-39538 to explain separate reporting by subsidiaries.

The filing explicitly references SEC Release No. 34-39538 and states certain Vanguard subsidiaries will report beneficial ownership separately. The statement documents a compliance-driven reporting change, not an acquisition or disposition.

Check future filings from The Vanguard Group entities for any subsidiary schedules that may report holdings previously aggregated under Vanguard.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What does The Vanguard Group report for GMED ownership?

It reports 0 shares beneficially owned, representing 0% of Common Stock. The filing is an amendment explaining a Vanguard internal realignment dated January 12, 2026, with subsidiaries to report separately.

Does this filing signal a sale or purchase of GMED shares by Vanguard?

No; the amendment is a reporting change rather than a trade. It documents disaggregation of reporting under SEC Release No. 34-39538, not an explicit purchase or sale transaction or cash flow related to GMED.

Why does Vanguard say subsidiaries will report separately for GMED?

Vanguard cites an internal realignment on January 12, 2026 and relies on SEC Release No. 34-39538 to disaggregate beneficial ownership reporting, so certain subsidiaries will file separately instead of under The Vanguard Group umbrella.

Will future Vanguard filings show GMED holdings again?

Possibly; the amendment states subsidiaries will report separately. Look for additional Schedule 13G/A entries from Vanguard-affiliated subsidiaries that may disclose any positions previously aggregated under The Vanguard Group.





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


SCHEDULE 13G



The Vanguard Group
Signature:Ashley Grim
Name/Title:Head of Global Fund Administration
Date:03/26/2026